tiprankstipranks
AstraZeneca PLC (GB:AZN)
LSE:AZN
UK Market
Want to see GB:AZN full AI Analyst Report?

AstraZeneca (AZN) Share Forecast & Price Target

926 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
12 Buy
2 Hold
1 Sell
Based on 15 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

16,446.55 p
▲(8.79% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 16,446.55 p with a high forecast of 20,500.00 p and a low forecast of 11,300.00 p. The average price target represents a 8.79% change from the last price of 15,118.00 p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10222":"10,222 p","20501":"20,501 p","12791.75":"12,791.8 p","15361.5":"15,361.5 p","17931.25":"17,931.3 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">21K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16446.55112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">16K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[10222,12791.75,15361.5,17931.25,20501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15022,15443.384615384615,15864.76923076923,16286.153846153846,16707.53846153846,17128.923076923078,17550.30769230769,17971.69230769231,18393.076923076922,18814.46153846154,19235.846153846152,19657.23076923077,20078.615384615383,{"y":20500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15022,15131.580855384615,15241.161710769231,15350.742566153845,15460.323421538462,15569.904276923076,15679.485132307693,15789.065987692307,15898.646843076924,16008.227698461538,16117.808553846155,16227.38940923077,16336.970264615386,{"y":16446.55112,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15022,14735.692307692309,14449.384615384615,14163.076923076924,13876.76923076923,13590.461538461539,13304.153846153846,13017.846153846154,12731.538461538461,12445.23076923077,12158.923076923076,11872.615384615385,11586.307692307691,{"y":11300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11171.301,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10426.285,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10392.868,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10223.814,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10913.788,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11728.389,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12308.375,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12342.026,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13694.008,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13648.479,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13895.914,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15252,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15022,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target20,500 pAverage Price Target16,447 pLowest Price Target11,300 p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
16,500 p
Buy
9.14%
Upside
Reiterated
04/29/26
AstraZeneca (AZN) Gets a Buy from Barclays
Deutsche Bank  Analyst forecast on GB:AZN
Deutsche Bank
Deutsche Bank
11,500 p
Sell
-23.93%
Downside
Reiterated
04/28/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
J.P. Morgan Analyst forecast on GB:AZN
J.P. Morgan
J.P. Morgan
16,000 p
Buy
5.83%
Upside
Reiterated
04/21/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on GB:AZN
Goldman Sachs
Goldman Sachs
16,600 p
Buy
9.80%
Upside
Reiterated
04/21/26
BUY Rating on AstraZeneca Driven by Camizestrant’s Phase III SERENA-6 PFS2 Catalyst and Key FDA ODAC Milestone in HR+ Breast Cancer
Morgan Stanley Analyst forecast on GB:AZN
Morgan Stanley
Morgan Stanley
16,500 p
Buy
9.14%
Upside
Reiterated
04/13/26
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
UBS
17,600 p
Buy
16.42%
Upside
Reiterated
04/10/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
Citi
17,000 p18,000 p
Buy
19.06%
Upside
Reiterated
04/10/26
AstraZeneca (AZN) Gets a Buy from Citi
Jefferies
18,000 p
Buy
19.06%
Upside
Reiterated
04/10/26
Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on GB:AZN
Bank of America Securities
Bank of America Securities
16,500 p
Buy
9.14%
Upside
Reiterated
04/01/26
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
Guggenheim
16,000 p16,500 p
Buy
9.14%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on GB:AZN
TD Cowen
TD Cowen
17,751.72 p
Buy
17.42%
Upside
Reiterated
03/18/26
AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating
Bernstein Analyst forecast on GB:AZN
Bernstein
Bernstein
1,063 p20,500 p
Buy
35.60%
Upside
Reiterated
03/18/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on GB:AZN
Berenberg Bank
Berenberg Bank
17,000 p
Buy
12.45%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
DZ BANK AG Analyst forecast on GB:AZN
DZ BANK AG
DZ BANK AG
Hold
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Kepler Capital  Analyst forecast on GB:AZN
Kepler Capital
Kepler Capital
11,300 p
Hold
-25.25%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
16,500 p
Buy
9.14%
Upside
Reiterated
04/29/26
AstraZeneca (AZN) Gets a Buy from Barclays
Deutsche Bank  Analyst forecast on GB:AZN
Deutsche Bank
Deutsche Bank
11,500 p
Sell
-23.93%
Downside
Reiterated
04/28/26
AstraZeneca (AZN) Gets a Sell from Deutsche Bank
J.P. Morgan Analyst forecast on GB:AZN
J.P. Morgan
J.P. Morgan
16,000 p
Buy
5.83%
Upside
Reiterated
04/21/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on GB:AZN
Goldman Sachs
Goldman Sachs
16,600 p
Buy
9.80%
Upside
Reiterated
04/21/26
BUY Rating on AstraZeneca Driven by Camizestrant’s Phase III SERENA-6 PFS2 Catalyst and Key FDA ODAC Milestone in HR+ Breast Cancer
Morgan Stanley Analyst forecast on GB:AZN
Morgan Stanley
Morgan Stanley
16,500 p
Buy
9.14%
Upside
Reiterated
04/13/26
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
UBS
17,600 p
Buy
16.42%
Upside
Reiterated
04/10/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
Citi
17,000 p18,000 p
Buy
19.06%
Upside
Reiterated
04/10/26
AstraZeneca (AZN) Gets a Buy from Citi
Jefferies
18,000 p
Buy
19.06%
Upside
Reiterated
04/10/26
Jefferies Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on GB:AZN
Bank of America Securities
Bank of America Securities
16,500 p
Buy
9.14%
Upside
Reiterated
04/01/26
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
Guggenheim
16,000 p16,500 p
Buy
9.14%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on GB:AZN
TD Cowen
TD Cowen
17,751.72 p
Buy
17.42%
Upside
Reiterated
03/18/26
AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating
Bernstein Analyst forecast on GB:AZN
Bernstein
Bernstein
1,063 p20,500 p
Buy
35.60%
Upside
Reiterated
03/18/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on GB:AZN
Berenberg Bank
Berenberg Bank
17,000 p
Buy
12.45%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
DZ BANK AG Analyst forecast on GB:AZN
DZ BANK AG
DZ BANK AG
Hold
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Kepler Capital  Analyst forecast on GB:AZN
Kepler Capital
Kepler Capital
11,300 p
Hold
-25.25%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
xxx
Success Rate
14/22 ratings generated profit
64%
Average Return
+3.74%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +3.74% per trade.
1 Year
Success Rate
35/39 ratings generated profit
90%
Average Return
+16.87%
Copying Matthew Weston's trades and holding each position for 1 Year would result in 89.74% of your transactions generating a profit, with an average return of +16.87% per trade.
2 Years
xxx
Success Rate
35/39 ratings generated profit
90%
Average Return
+22.93%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.74% of your transactions generating a profit, with an average return of +22.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
34
29
29
41
40
Hold
2
1
2
2
2
Sell
6
5
5
7
7
Strong Sell
0
0
0
0
0
total
42
35
36
50
49
In the current month, AZN has received 40 Buy Ratings, 2 Hold Ratings, and 7 Sell Ratings. AZN average Analyst price target in the past 3 months is 16,446.55.
Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

AZN Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 16,446.55.
    What is GB:AZN’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 8.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 2 hold ratings and 1 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 16,446.55. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 20,500.00 p ,and the lowest forecast is 11,300.00 p. The average share price target represents 8.79% Increase from the current price of 15,118 p.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.